BMJ  2008;336:170 (26 January), doi:10.1136/bmj.39469.465139.80

Editorials

Mandatory disclosure of trial results for drugs and devices

New US law will require public posting of all the main results and data on harms

The first 150 words of the full text of this article appear below.

Last week the drug industry was shown, twice, to have suppressed trial results that were commercially unfavourable—an all too familiar tale.^{1 2} But from September 2008, a new US law will mandate the public disclosure of such results, and it will no longer be left to investigative journalists and other researchers to dig out the findings of trials.

The FDA Amendments Act, passed quietly last year, rules that any ongoing clinical trial involving a drug, biological product, or device regulated by the US Food and Drug Administration (FDA) must be registered at clinicaltrials.gov and that, from 27 September 2008, triallists must start to post in that same registry the results of those trials.³ This applies to all clinical trials of drugs and devices except phase I drug trials (preliminary safety studies for new products) and small feasibility studies of a device. Furthermore, it covers all trials—whether or not they are conducted . . . [Full text of this article]

¹ BMJ, London WC1H 9JR

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Patients and the public deserve big changes in evaluation of drugs

Silvio Garattini and Iain Chalmers
BMJ 2009 338: b1025. [Extract] [Full Text]

Research methods and reporting

Trish Groves
BMJ 2008 337: a2201. [Extract] [Full Text]

Open access to research

Fiona Godlee
BMJ 2008 337: a1051. [Extract] [Full Text]

A legal framework for drug safety
BMJ 2008 336: 0. [Extract] [Full Text]

An untold story?

Jeanne Lenzer and Shannon Brownlee
BMJ 2008 336: 532-534. [Extract] [Full Text] [PDF]

Unreported cholesterol drug data released by company

Jeanne Lenzer
BMJ 2008 336: 180-181. [Extract] [Full Text] [PDF]

Clinical trial registration

Christine Laine, Richard Horton, Catherine D DeAngelis, Jeffrey M Drazen, Frank A Frizelle, Fiona Godlee, Charlotte Haug, Paul C Hébert, Sheldon Kotzin, Ana Marusic, Peush Sahni, Torben V Schroeder, Harold C Sox, Martin B Van Der Weyden, and Freek W A Verheugt
BMJ 2007 334: 1177-1178. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Tse, T., Williams, R. J., Zarin, D. A. (2009). Reporting "Basic Results" in ClinicalTrials.gov. Chest 136: 295-303 [Full text]  
• Garattini, S., Chalmers, I. (2009). Patients and the public deserve big changes in evaluation of drugs. BMJ 338: b1025-b1025 [Full text]  
• Langdon-Neuner, E. (2009). When Does Previous Disclosure Become a 'Prior Publication' Problem?. Chest 135: 233-237 [Full text]  
• Groves, T. (2008). Research methods and reporting. BMJ 337: a2201-a2201 [Full text]  
• Godlee, F. (2008). Open access to research. BMJ 337: a1051-a1051 [Full text]  
• Lenzer, J., Brownlee, S. (2008). An untold story?. BMJ 336: 532-534 [Full text]  

Online poll

Find out more >>